O’Donnell, P. H., Hoimes, C. J., Rosenberg, J. E., Petrylak, D. P., Mar, N., Barata, P. C., … Flaig, T. W. (2024). Study EV-103: Neoadjuvant treatment with enfortumab vedotin monotherapy in cisplatin-ineligible patients with muscle invasive bladder cancer (MIBC)-2-year event-free survival and safety data for Cohort H. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 42).

O’Donnell, Peter H., Christopher J. Hoimes, Jonathan E. Rosenberg, Daniel P. Petrylak, Nataliya Mar, Pedro C. Barata, Sandy Srinivas, et al. “Study EV-103: Neoadjuvant treatment with enfortumab vedotin monotherapy in cisplatin-ineligible patients with muscle invasive bladder cancer (MIBC)-2-year event-free survival and safety data for Cohort H.” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 42, 2024.

O’Donnell PH, Hoimes CJ, Rosenberg JE, Petrylak DP, Mar N, Barata PC, et al. Study EV-103: Neoadjuvant treatment with enfortumab vedotin monotherapy in cisplatin-ineligible patients with muscle invasive bladder cancer (MIBC)-2-year event-free survival and safety data for Cohort H. In: JOURNAL OF CLINICAL ONCOLOGY. 2024.

O’Donnell, Peter H., et al. “Study EV-103: Neoadjuvant treatment with enfortumab vedotin monotherapy in cisplatin-ineligible patients with muscle invasive bladder cancer (MIBC)-2-year event-free survival and safety data for Cohort H.” JOURNAL OF CLINICAL ONCOLOGY, vol. 42, no. 16, 2024.

O’Donnell PH, Hoimes CJ, Rosenberg JE, Petrylak DP, Mar N, Barata PC, Srinivas S, Gourdin TS, Henry E, Bilen MA, George S, Rao S, Assikis VJ, Burgess EF, Lewis BE, Bowman IA, Brancato SJ, Mildiner-Earley S, Zhu Y, Flaig TW. Study EV-103: Neoadjuvant treatment with enfortumab vedotin monotherapy in cisplatin-ineligible patients with muscle invasive bladder cancer (MIBC)-2-year event-free survival and safety data for Cohort H. JOURNAL OF CLINICAL ONCOLOGY. 2024.